Shanghai ZJ Bio-Tech Co. Ltd. A Net Assets
Shanghai ZJ Bio-Tech Co. Ltd. A net assets. Based on the latest financial reports, Shanghai ZJ Bio-Tech Co. Ltd. A (688317) has net assets worth CN¥3.26 Billion CNY (≈ $477.13 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.66 Billion ≈ $535.03 Million USD) and total liabilities (CN¥395.66 Million ≈ $57.90 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 688317 net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.26 Billion |
| % of Total Assets | 89.18% |
| Annual Growth Rate | 32.15% |
| 5-Year Change | -12.5% |
| 10-Year Change | 592.05% |
| Growth Volatility | 76.52 |
Net Assets of Shanghai ZJ Bio-Tech Co. Ltd. A (2013–2025)
Net assets of Shanghai ZJ Bio-Tech Co. Ltd. A from 2013 to 2025. This chart illustrates how Shanghai ZJ Bio-Tech Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See Shanghai ZJ Bio-Tech Co. Ltd. A net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Shanghai ZJ Bio-Tech Co. Ltd. A (2013–2025)
The table below shows the annual net assets of Shanghai ZJ Bio-Tech Co. Ltd. A from 2013 to 2025. For live market cap and overall valuation, see Shanghai ZJ Bio-Tech Co. Ltd. A market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.35 Billion ≈ $490.04 Million |
-7.92% |
| 2024-12-31 | CN¥3.64 Billion ≈ $532.19 Million |
-4.92% |
| 2023-12-31 | CN¥3.82 Billion ≈ $559.71 Million |
-8.94% |
| 2022-12-31 | CN¥4.20 Billion ≈ $614.65 Million |
+9.75% |
| 2021-12-31 | CN¥3.83 Billion ≈ $560.07 Million |
+161.69% |
| 2020-12-31 | CN¥1.46 Billion ≈ $214.02 Million |
+155.77% |
| 2019-12-31 | CN¥571.84 Million ≈ $83.68 Million |
+7.36% |
| 2018-12-31 | CN¥532.66 Million ≈ $77.95 Million |
+12.69% |
| 2017-12-31 | CN¥472.70 Million ≈ $69.17 Million |
-2.32% |
| 2016-12-31 | CN¥483.90 Million ≈ $70.81 Million |
+40.89% |
| 2015-12-31 | CN¥343.47 Million ≈ $50.26 Million |
+211.26% |
| 2014-12-31 | CN¥110.35 Million ≈ $16.15 Million |
-6.50% |
| 2013-12-31 | CN¥118.03 Million ≈ $17.27 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai ZJ Bio-Tech Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3004.6% over the analyzed period, indicating profitable operations and earnings retention.
Shanghai ZJ Bio-Tech Co. Ltd. A Net Assets Breakdown (December 2025)
Shanghai ZJ Bio-Tech Co. Ltd. A net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.31 Billion | 39.21% |
| Other Components | CN¥2.04 Billion | 60.79% |
| Total Equity | CN¥3.35 Billion | 100.00% |
Shanghai ZJ Bio-Tech Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shanghai ZJ Bio-Tech Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shinhan Alpha REIT Co Ltd
KO:293940
|
$457.33 Million |
|
Yieh United Steel
TWO:9957
|
$457.37 Million |
|
Guggenheim Active Allocation Fund
NYSE:GUG
|
$457.43 Million |
|
Concord Securities Co Ltd
TWO:6016
|
$457.51 Million |
|
One Liberty Properties Inc
NYSE:OLP
|
$456.93 Million |
|
RPG Life Sciences Limited
NSE:RPGLIFE
|
$456.76 Million |
|
Hanssem
KO:009240
|
$456.74 Million |
|
Zhongrui Co Ltd
SHE:301587
|
$456.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai ZJ Bio-Tech Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,636,886,762 to 3,348,848,912, a change of -288,037,850 (-7.9%).
- Net loss of 34,303,800 reduced equity.
- Dividend payments of 3,032,196 reduced retained earnings.
- Other comprehensive income decreased equity by 89,505,606.
- Other factors decreased equity by 161,196,248.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-34.30 Million | -1.02% |
| Dividends Paid | CN¥3.03 Million | -0.09% |
| Other Comprehensive Income | CN¥-89.51 Million | -2.67% |
| Other Changes | CN¥-161.20 Million | -4.81% |
| Total Change | CN¥- | -7.92% |
Book Value vs Market Value Analysis
This analysis compares Shanghai ZJ Bio-Tech Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.89x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 17.20x to 0.89x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥0.96 | CN¥16.45 | x |
| 2014-12-31 | CN¥1.80 | CN¥16.45 | x |
| 2015-12-31 | CN¥2.53 | CN¥16.45 | x |
| 2016-12-31 | CN¥3.28 | CN¥16.45 | x |
| 2017-12-31 | CN¥3.24 | CN¥16.45 | x |
| 2018-12-31 | CN¥3.65 | CN¥16.45 | x |
| 2019-12-31 | CN¥3.88 | CN¥16.45 | x |
| 2020-12-31 | CN¥10.01 | CN¥16.45 | x |
| 2021-12-31 | CN¥20.08 | CN¥16.45 | x |
| 2022-12-31 | CN¥21.71 | CN¥16.45 | x |
| 2023-12-31 | CN¥19.84 | CN¥16.45 | x |
| 2024-12-31 | CN¥19.12 | CN¥16.45 | x |
| 2025-12-31 | CN¥18.55 | CN¥16.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai ZJ Bio-Tech Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27.46%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.12x
- Recent ROE (-1.02%) is below the historical average (15.50%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 25.09% | 35.09% | 0.50x | 1.44x | CN¥17.79 Million |
| 2014 | 31.75% | 34.63% | 0.51x | 1.81x | CN¥23.97 Million |
| 2015 | 9.47% | 25.67% | 0.32x | 1.15x | CN¥-1.81 Million |
| 2016 | 10.07% | 31.11% | 0.30x | 1.09x | CN¥362.05K |
| 2017 | 10.90% | 26.74% | 0.37x | 1.09x | CN¥4.26 Million |
| 2018 | 11.70% | 27.78% | 0.39x | 1.09x | CN¥9.05 Million |
| 2019 | 9.01% | 19.90% | 0.40x | 1.12x | CN¥-5.66 Million |
| 2020 | 63.72% | 45.42% | 1.09x | 1.29x | CN¥785.75 Million |
| 2021 | 19.82% | 37.57% | 0.47x | 1.11x | CN¥375.78 Million |
| 2022 | 18.10% | 32.68% | 0.49x | 1.13x | CN¥340.23 Million |
| 2023 | -3.58% | -49.89% | 0.07x | 1.07x | CN¥-519.35 Million |
| 2024 | -3.50% | -71.35% | 0.05x | 1.04x | CN¥-491.15 Million |
| 2025 | -1.02% | -27.46% | 0.03x | 1.12x | CN¥-369.19 Million |
Industry Comparison
This section compares Shanghai ZJ Bio-Tech Co. Ltd. A's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,728,515,784
- Average return on equity (ROE) among peers: 10.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai ZJ Bio-Tech Co. Ltd. A (688317) | CN¥3.26 Billion | 25.09% | 0.12x | $456.98 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $3.98 Billion | -16.09% | 0.31x | $384.61 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $143.67 Million | 40.91% | 1.23x | $4.24 Billion |
| Double Medical Technology Inc (002901) | $2.59 Billion | 26.01% | 0.31x | $2.56 Billion |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $5.66 Billion | -0.29% | 0.06x | $494.04 Million |
| Lepu Medical Tech Beijing (300003) | $8.00 Billion | 21.55% | 0.99x | $3.40 Billion |
| INKON Life Technology Co Ltd (300143) | $727.00 Million | 5.81% | 0.17x | $817.03 Million |
| Edan Instruments Inc (300206) | $1.23 Billion | 2.15% | 0.20x | $1.02 Billion |
| Guangdong Biolight Meditech Co Ltd (300246) | $393.88 Million | 7.34% | 0.20x | $505.98 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.09 Billion | 11.74% | 0.48x | $473.66 Million |
| Sinocare Inc (300298) | $3.47 Billion | 8.19% | 0.71x | $1.56 Billion |
About Shanghai ZJ Bio-Tech Co. Ltd. A
Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular diagnostic reagents and instruments in China and internationally. The company offers nucleic acid and real-time PCR kits, as well as consumables. It serves public health safety and clinical diagnostics sectors. The company was founded in 2005 and is based in Shanghai, China.